Inhibikase Therapeutics, Inc. Financial Ratios
IKT|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-173.3%
Profit Margin
-7304.7%
Net Income / Revenue
Asset Turnover
0.00
Revenue / Total Assets
Equity Multiplier
8.98
Total Assets / Equity
Composite: -173.3% (reported: -173.3%)
Profitability
Liquidity
Current Ratio
26.37
Quick Ratio
26.37
Solvency
Interest Coverage
-17.05
Efficiency
Asset Turnover
0.00
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2024 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-1.7%
+3.2pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.